The combination of bortezomib, cyclophosphamide, and dexamethasone (CyBorD, or CVD) is a recently discovered but already widely used MM treatment regimen that produces rapid and profound responses. Because of its success in MM, recent investigations have explored the use of this regimen as a potential therapy for AL amyloidosis, since those with the disease have few treatment options. Currently, the most effective treatment for AL amyloidosis is high-dose melphalan and autologous stem cell transplant; however, most patients are ineligible for this aggressive and difficult to tolerate approach due to organ damage common in patients with the disease.
Fortunately for AL amyloidosis patients, there is hope for a better treatment. Each of the studies summarized below conclude that treatment with the novel CyBorD/CVD regimen can lead to complete hematologic response and may allow AL amyloidosis patients to become eligible for stem cell transplants and live longer, higher quality lives.
STUDY 1: Cyclophosphamide-Bortezomib-Dexamethasone (CYBORD) Produces Rapid and Complete Hematological Response In Patients with AL Amyloidosis
First Author: Joseph Mikhael, MD, Mayo Clinic, Scottsdale, AZ
Background
Results
Conclusion
STUDY 2: Cyclophosphamide, Bortezomib and Dexamethasone Therapy in AL Amyloidosis is Associated with High Clonal Response Rates and Prolonged Progression Free Survival
First Author: Christopher Venner, MD, National Amyloidosis Centre, University College London Medical School, London, United Kingdom
###
Blood